中樞神經系統生物標記市場規模、佔有率、成長分析（按類型、應用、最終用戶和地區）- 產業預測，2025 年至 2032 年

2023 年全球中樞神經系統生物標記市場規模為 560 萬美元，預計將從 2024 年的 605 萬美元成長到 2032 年的 1129 萬美元，預測期內（2025-2032 年）的複合年成長率為 8.1%。

受神經系統疾病發病率上升、人口老化和生活方式改變的推動，全球中樞神經系統生物標記市場正在強勁成長。這種快速成長推動了對準確早期診斷的需求，並促進了基於生物標記的工具的整合。技術和研究的進步正在闡明中樞神經系統疾病的分子基礎，為具有更高敏感性、特異性和預測能力的創新生物標記鋪平了道路。對個人化醫療的關注凸顯了生物標記分析對於確定最佳患者群體和追蹤治療反應的重要性。雖然製藥業非常重視藥物開發和臨床試驗中的這些生物標記，但它面臨著諸如解決道德和監管問題以及標準化協議和檢驗檢測的需求等挑戰。整體而言，該領域正處於神經病學變革發展的巔峰。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

中樞神經系統生物標記市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 安全生物標記
• 療效生物標記
• 檢驗生物標記

中樞神經系統生物標記市場規模（按應用和複合年成長率）（2025-2032）

• 市場概況
• 診斷
  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 中風
• 藥物研發
  • 臨床前研究
  • 臨床試驗
• 個人化醫療
  • 基因生物標記
  • 蛋白質體生物標記
  • 代謝體學物標誌物

中樞神經系統生物標記市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院
• 診斷實驗室
• 研究組織
• 生物製藥公司

中樞神經系統生物標記市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Novartis AG（Switzerland）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific Inc.（USA）
• Abbott Laboratories（USA）
• Merck KGaA（Germany）
• Eurofins Scientific（Luxembourg）
• Charles River Laboratories International, Inc.（USA）
• PerkinElmer Inc.（USA）
• Bio-Rad Laboratories, Inc.（USA）
• QIAGEN NV（Netherlands）
• Axon Neuroscience SE（Slovakia）
• Alector Inc.（USA）
• Oryzon Genomics SA（Spain）
• Banyan Biomarkers Inc.（USA）
• Avacta Group PLC（UK）
• Geno Technology Inc.（USA）
• Anavex Life Sciences Corp.（USA）
• Alseres Pharmaceuticals Inc.（USA）
• Aposense Ltd.（Israel）

結論和建議

Global Central Nervous System Biomarkers Market size was valued at USD 5.6 million in 2023 and is poised to grow from USD 6.05 million in 2024 to USD 11.29 million by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global CNS biomarker market is witnessing robust growth, propelled by the rising incidence of neurological disorders, an aging population, and evolving lifestyles. This surge is prompting a heightened demand for precise, early diagnostics, fostering the integration of biomarker-based tools. Advances in technology and research are elucidating the molecular foundations of CNS disorders, paving the way for innovative biomarkers that enhance sensitivity, specificity, and predictive power. The focus on personalized medicine emphasizes the importance of biomarker analysis in identifying optimal patient groups and tracking treatment responses. While the pharmaceutical industry values these biomarkers for drug development and clinical trials, the market faces challenges including the need for standardized protocols and validated assays, along with addressing ethical and regulatory concerns. Overall, the sector is set for transformative developments in neurology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Biomarkers Market Segmental Analysis

Global Central Nervous System Biomarkers Market is segmented by Type, Application, End-User and region. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Application, the market is segmented into Diagnostics, Drug Discovery & Development and Personalized Medicine. Based on End-User, the market is segmented into Hospitals, Diagnostic Laboratories, Research Institutes and Biopharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Biomarkers Market

The global market for Central Nervous System (CNS) biomarkers is significantly driven by the escalating incidence of neurological disorders, including conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. As the prevalence of these ailments continues to rise globally, there is an increasing need for precise and timely diagnostic solutions. This heightened demand emphasizes the importance of biomarker-based diagnostic tools, which are essential for early detection and management of CNS disorders. Consequently, the surge in the number of individuals affected by these conditions propels the growth of the CNS biomarkers market, highlighting the urgent necessity for innovative diagnostic advancements.

Restraints in the Global Central Nervous System Biomarkers Market

One significant restraint in the Global Central Nervous System (CNS) Biomarkers market is the intricate nature of CNS disorders. These conditions are typically characterized by their multifactorial aspects, which complicate the process of pinpointing reliable and specific biomarkers. The diversity and variability within CNS disorders create obstacles in establishing universal biomarkers that can effectively and accurately represent the underlying disease mechanisms. This complexity not only hampers the standardization of biomarker development but also adds to the challenges faced by researchers and healthcare professionals in diagnosing and monitoring CNS diseases, thereby impacting market growth.

Market Trends of the Global Central Nervous System Biomarkers Market

The Global Central Nervous System (CNS) Biomarkers market is experiencing a notable upward trend driven by rapid technological advancements. Innovations like high-throughput screening, next-generation sequencing, and sophisticated imaging techniques significantly enhance the sensitivity and specificity of biomarker detection and analysis. These improvements enable more accurate diagnoses and effective monitoring of CNS disorders, fostering better clinical outcomes. Moreover, as healthcare providers increasingly adopt these technologies, the demand for reliable and precise biomarkers is escalating. This trend is expected to fuel investment in research and development, ultimately positioning CNS biomarkers as a crucial element in personalized medicine and targeted therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Central Nervous System Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

Global Central Nervous System Biomarkers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Stroke
• Drug Discovery & Development
  • Preclinical Studies
  • Clinical Trials
• Personalized Medicine
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers

Global Central Nervous System Biomarkers Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Biopharmaceutical Companies

Global Central Nervous System Biomarkers Market Size & CAGR (2025-2032)

• North America (Type, Application, End-User)
  • US
  • Canada
• Europe (Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axon Neuroscience SE (Slovakia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oryzon Genomics S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Banyan Biomarkers Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avacta Group PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Geno Technology Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alseres Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aposense Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations